XEN1101

DRUG6 trials

Sponsors

Xenon Pharmaceuticals Inc., James Murrough

Conditions

Focal EpilepsyFocal Onset SeizuresMajor Depressive DisorderPrimary Generalized Tonic-Clonic SeizuresTonic-Clonic Seizures

Phase 2

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Active, not recruitingNCT03796962

Xenon Pharmaceuticals Inc.Focal Epilepsy

Start: 2019-01-30End: 2028-10-31Updated: 2024-09-24

XEN1101 for Major Depressive Disorder

CompletedNCT04827901

James MurroughMajor Depressive Disorder

Start: 2021-10-19End: 2024-11-07Updated: 2025-04-02

Phase 3

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

CompletedNCT05614063

Xenon Pharmaceuticals Inc.Focal Onset Seizures

Start: 2022-11-18End: 2026-02-03Updated: 2026-05-14

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

RecruitingNCT05667142

Xenon Pharmaceuticals Inc.Primary Generalized Tonic-Clonic Seizures

Start: 2023-02-14End: 2027-06-01Target: 160Updated: 2026-08-10

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

RecruitingNCT05716100

Xenon Pharmaceuticals Inc.Focal Onset Seizures

Start: 2023-05-09End: 2026-12-01Target: 360Updated: 2026-05-14

An Open-label Study of XEN1101 in Epilepsy

Enrolling by invitationNCT05718817

Xenon Pharmaceuticals Inc.Focal Epilepsy, Tonic-Clonic Seizures

Start: 2023-04-25End: 2033-06-01Target: 880Updated: 2026-09-11

Related Papers

Azetukalner, a Novel K<sub>V</sub>7 Potassium Channel Opener, in Adults With Major Depressive Disorder

JAMA Network Open2025-05-271 citations

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy

JAMA Neurology2023-10-0938 citations